piperacillin/tazobactam kabi 4 g/0,5 g 4 g/1 bočica+ 0,5 g/1 bočica prašak za rastvor za infuziju
amicus pharma d.o.o. - piperacilin, tazobaktam - prašak za rastvor za infuziju - 4 g/1 bočica+ 0,5 g/1 bočica - svaka bočica praška za rastvor za infuziju sadrži: 4 g piperacilina u obliku piperacilin natrijuma i 0,5 g tazobaktama u obliku tazobaktam natrijuma.
modigraf
astellas pharma europe b.v. - takrolimus - odbacivanje transplantata - imunosupresivi - profilaksa odbacivanja transplantata u primateljima odraslih i dječjih, bubrega, jetre ili srčanih transplantata. i pedijatrijska bolesnika liječenje отторжении otporne na liječenje drugih иммуносупрессивных lijekova kod odraslih .
myclausen
passauer pharma gmbh - mikofenolat mofetil - odbacivanje transplantata - imunosupresivi - myclausen je indiciran u kombinaciji sa ciklosporin i kortikosteroidi za profilaksa akutnog transplantaciju odbacivanja u bolesnika koji su primali alogene transplantacije bubrega, srca ili jetre.
mycophenolate mofetil teva
teva pharma b.v. - mikofenolat mofetil - odbacivanje transplantata - imunosupresivi - mikofenolat mofetil teva je indiciran u kombinaciji sa ciklosporin i kortikosteroidi za profilaksa akutnog transplantaciju odbacivanja u bolesnika koji su primali alogene transplantacije bubrega, srca ili jetre.
myfenax
teva b.v. - mikofenolat mofetil - odbacivanje transplantata - imunosupresivi - myfenax je indiciran u kombinaciji sa ciklosporin i kortikosteroidi za profilaksa akutnog transplantaciju odbacivanja u bolesnika koji su primali alogene transplantacije bubrega, srca ili jetre.
advagraf
astellas pharma europe bv - takrolimus - odbacivanje transplantata - imunosupresivi - profilaksa odbacivanja transplantata kod odraslih primatelja bubrega ili jetrenih transplantata. liječenje odbacivanja alografta otpornih na liječenje drugim imunosupresivnim lijekovima u odraslih bolesnika.
jayempi
nova laboratories ireland limited - azathioprine - odbacivanje transplantata - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.
lysobact p spray s aromom banane 20 mg/1 ml+ 10 mg/1 ml sprej za usnu sluznicu, otopina
bosnalijek d.d. - lizozim, piridoksin - sprej za usnu sluznicu, otopina - 20 mg/1 ml+ 10 mg/1 ml - 1 ml spreja za usnu sluznicu, otopine sadrži: 20 mg lizozim hidroklorida, 10 mg piridoksin klorida
merobocid 1000 mg/1 bočica prašak za rastvor za injekciju
doo ˝farmacija 2011˝ bihać - Меропенем - prašak za rastvor za injekciju - 1000 mg/1 bočica - 1 bočica sadrži: 1000 mg meropenema (u obliku meropenem trihidrata)
cebopim 1 g/1 bočica prašak za rastvor za injekciju
doo ˝farmacija 2011˝ bihać - cefepim - prašak za rastvor za injekciju - 1 g/1 bočica - jedna bočica sadrži 1g cefepima (u obliku cefepim dihlorid monohidrata)